In-vitro nebulised dose emission characteristics of a tobramycin solution (75mg/ml) using an I-Neb (I-NEB) and a pari LC+ driven by a TurboBoy compressor (PARI) nebuliser Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Relative lung deposition of tobramycin from a MicroAir nebuliser Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007
Assessment on the efficiency of Clenny Aerosol, a new jet nebulizer with breath-enhanced bulb Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001
Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI) Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
The effect of nebulizer systems in inhaled tobramycin Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003
Similar delivery of ipratropium bromide is possible at approximately one-half dose via a breath-actuated nebulizer compared with a continuous nebulizer Source: Eur Respir J 2005; 26: Suppl. 49, 306s Year: 2005
In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Aerosol characterization of three corticosteroids in MDIs plus a new spacer device (Fluspacer®) vs MDIs alone Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001
Comparison of tobramycin 80 mg (IV-Preparation) and 300 mg solution for inhalation in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
In vitro aerosol delivery by vibrating mesh nebulizer (VMN) and pressurized metered dose inhaler (pMDI) using spacers in comparison with T adapters in mechanical ventilation. Source: Respiratory Failure and Mechanical Ventilation Conference 2020 Year: 2020
In vitro comparison of Pulmicort Respules™ with Clenil® pro aerosol in combination with three nebulisersSource: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002
Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Lung deposition of two bronchodilators in subjects with (COPD) when administered via standard jet nebulizer or Handihaler® using functional respiratory imaging (FRI). Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001